Screener
Sarepta Therapeutics, Inc. SRPT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Accrued expenses | 325,232 | 359,659 |
| Deferred revenue, current portion | 110,132 | 443,397 |
| Other current liabilities | 16,562 | 11,393 |
| Total current liabilities | 502,908 | 1,095,290 |
| Long-term debt | 847,623 | 828,974 |
| Lease liabilities, net of current portion | 198,226 | 199,378 |
| Deferred revenue, net of current portion | 110,132 | 83,910 |
| Other non-current liabilities | 1,825 | 1,529 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s total current liabilities?
- Sarepta Therapeutics, Inc. (SRPT) reported total current liabilities of $502.91M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Sarepta Therapeutics, Inc.'s total current liabilities decreased by 45.3% year-over-year, from $919.95M to $502.91M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s total current liabilities has grown at a 21.4% compound annual growth rate (CAGR), from $416.03M to $1.1B.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Sarepta Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude